Literature DB >> 31131955

Single-nucleotide editing: From principle, optimization to application.

Jinling Tang1, Trevor Lee2, Tao Sun1.   

Abstract

Cytosine base editors (CBEs) and adenine base editors (ABEs), which are generally composed of an engineered deaminase and a catalytically impaired CRISPR-Cas9 variant, are new favorite tools for single base substitution in cells and organisms. In this review, we summarize the principle of base-editing systems and elaborate on the evolution of different platforms of CBEs and ABEs, including their deaminase, Cas9 variants, and editing outcomes. Moreover, we highlight their applications in mouse and human cells and discuss the challenges and prospects of base editors. The ABE- and CBE systems have been used in gene silencing, pathogenic gene correction, and functional genetic screening. Single base editing is becoming a new promising genetic tool in biomedical research and gene therapy.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  CRISPR-Cas9; adenine base editors; base editing; cytosine base editors; genetic engineering

Mesh:

Substances:

Year:  2019        PMID: 31131955      PMCID: PMC6874907          DOI: 10.1002/humu.23819

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  90 in total

1.  CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations.

Authors:  Cem Kuscu; Mahmut Parlak; Turan Tufan; Jiekun Yang; Karol Szlachta; Xiaolong Wei; Rashad Mammadov; Mazhar Adli
Journal:  Nat Methods       Date:  2017-06-05       Impact factor: 28.547

2.  Knockout mice created by TALEN-mediated gene targeting.

Authors:  Young Hoon Sung; In-Jeoung Baek; Duk Hyoung Kim; Jisun Jeon; Jaehoon Lee; Kyunghee Lee; Daewon Jeong; Jin-Soo Kim; Han-Woong Lee
Journal:  Nat Biotechnol       Date:  2013-01       Impact factor: 54.908

3.  The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours.

Authors:  Kirsten K Youngren; Douglas Coveney; Xiaoning Peng; Chitralekha Bhattacharya; Laura S Schmidt; Michael L Nickerson; Bruce T Lamb; Jian Min Deng; Richard R Behringer; Blanche Capel; Edward M Rubin; Joseph H Nadeau; Angabin Matin
Journal:  Nature       Date:  2005-05-19       Impact factor: 49.962

4.  Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.

Authors:  Qiurong Ding; Alanna Strong; Kevin M Patel; Sze-Ling Ng; Bridget S Gosis; Stephanie N Regan; Chad A Cowan; Daniel J Rader; Kiran Musunuru
Journal:  Circ Res       Date:  2014-06-10       Impact factor: 17.367

5.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Authors:  Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-06-25       Impact factor: 17.088

6.  Activation induced cytidine deaminase mutant (AID-His130Pro) from Hyper IgM 2 patient retained mutagenic activity on SHM artificial substrate.

Authors:  Hanen Ouadani; Imen Ben-Mustapha; Meriem Ben-Ali; Beya Larguèche; Tihana Jovanic; Sylvie Garcia; Benoit Arcangioli; Houda Elloumi-Zghal; Dahmani Fathallah; Mongia Hachicha; Hatem Masmoudi; François Rougeon; Mohamed-Ridha Barbouche
Journal:  Mol Immunol       Date:  2016-10-04       Impact factor: 4.407

7.  In vivo base editing of post-mitotic sensory cells.

Authors:  Wei-Hsi Yeh; Hao Chiang; Holly A Rees; Albert S B Edge; David R Liu
Journal:  Nat Commun       Date:  2018-06-05       Impact factor: 14.919

8.  Highly efficient base editing in human tripronuclear zygotes.

Authors:  Changyang Zhou; Meiling Zhang; Yu Wei; Yidi Sun; Yun Sun; Hong Pan; Ning Yao; Wanxia Zhong; Yixue Li; Weiping Li; Hui Yang; Zi-Jiang Chen
Journal:  Protein Cell       Date:  2017-10       Impact factor: 14.870

9.  Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions.

Authors:  S Piaskowski; M Bienkowski; E Stoczynska-Fidelus; R Stawski; M Sieruta; M Szybka; W Papierz; M Wolanczyk; D J Jaskolski; P P Liberski; P Rieske
Journal:  Br J Cancer       Date:  2011-02-15       Impact factor: 7.640

10.  High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

Authors:  Benjamin P Kleinstiver; Vikram Pattanayak; Michelle S Prew; Shengdar Q Tsai; Nhu T Nguyen; Zongli Zheng; J Keith Joung
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

View more
  4 in total

1.  Gene therapy for inherited arrhythmias.

Authors:  Vassilios J Bezzerides; Maksymilian Prondzynski; Lucie Carrier; William T Pu
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

2.  BEON: A Functional Fluorescence Reporter for Quantification and Enrichment of Adenine Base-Editing Activity.

Authors:  Peipei Wang; Li Xu; Yandi Gao; Renzhi Han
Journal:  Mol Ther       Date:  2020-04-16       Impact factor: 11.454

Review 3.  Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases.

Authors:  Meihua Luo; Leo Kit Cheung Lee; Bo Peng; Chung Hang Jonathan Choi; Wing Yin Tong; Nicolas H Voelcker
Journal:  Adv Sci (Weinh)       Date:  2022-07-18       Impact factor: 17.521

4.  Pycard and BC017158 Candidate Genes of Irm1 Locus Modulate Inflammasome Activation for IL-1β Production.

Authors:  Andrea Borrego; Francesca Colombo; Jean Gabriel de Souza; José Ricardo Jensen; Alice Dassano; Rocco Piazza; Barbara Anaís Rodrigues Dos Santos; Orlando Garcia Ribeiro; Marcelo De Franco; Wafa Hanna Koury Cabrera; Marcelo Yudi Icimoto; Nancy Starobinas; Geraldo Magalhães; Leticia Figueiredo Monteleone; Silas Fernandes Eto; Carlos DeOcesano-Pereira; Mauricio Barbugiani Goldfeder; Kerly Fernanda Mesquita Pasqualoto; Tommaso A Dragani; Olga Célia Martinez Ibañez
Journal:  Front Immunol       Date:  2022-06-21       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.